natgillin/translations-raw huggingface dataset:
In 7 clinical trials (6 placebo-controlled), individuals were administered Silgard or placebo on the day of enrolment and approximately 2 and 6 months thereafter. 
V 7 kliničnih preskušanjih (6 nadzorovanih s placebom) so osebe cepivo Silgard ali placebo prejele na dan vključitve in nato približno čez 2 in 6 mesecev.
Administer the entire dose as per standard protocol. 
Aplicirajte celotni odmerek cepiva po standardnem protokolu.
They are ranked under headings of frequency using the following convention: 
Pogostnost je navedena v skladu z naslednjim dogovorom:
Silgard is intended for adolescents and adults from 9 years of age onwards. 
Cepivo Silgard je namenjeno za mladostnike in odrasle od 9. leta starosti dalje.
The GMTs were somewhat lower than those reported in non-HIV infected subjects of the same age in other studies. 
Srednji geometrijski titri so bili nekoliko nižji od tistih, poročanih pri enako starih s HIV neokuženih osebah v drugih študijah.
Since no vaccine is 100% effective and Silgard will not provide protection against every HPV type, or against existing HPV infections, routine cervical screening remains critically important and should follow local recommendations. 
Ker učinkovitost nobenega cepiva ni 100-odstotna in ker cepivo Silgard ne ščiti pred vsemi tipi HPV oziroma pred že obstoječimi okužbami, rutinska presejanja raka materničnega vratu ostajajo kritičnega pomena in jih je treba izvajati v skladu z lokalnimi priporočili.
Human Papillomavirus = HPV 
20 mikrogramov humani papilomavirus = HPV
Silgard has not been shown to have a therapeutic effect. 
Ni bilo dokazano, da bi cepivo Silgard imelo terapevtski učinek.
Respiratory, thoracic and mediastinal disorders: Very rare: bronchospasm. 
Bolezni dihal, prsnega koša in mediastinalnega prostora: Zelo redki: bronhospazem
A subset of the study participants from the 2-dose group (n=50) were followed 5-years post-vaccination (Month 60 Postdose 1). 
Podskupino sodelujočih v študiji iz skupine z 2 odmerki (n=50) so spremljali 5 let po cepljenju (60. mesec po 1. odmerku).
The most common adverse reactions observed were injection-site adverse reactions (77.1% of vaccinees within 5 days following any vaccination visit) and headache (16.6% of the vaccinees). 
Najpogosteje opaženi neželeni učinki so bili neželeni učinki na mestu injiciranja (77,1 % cepljenih v 5 dneh po katerem koli obisku za cepljenje) in glavobol (16,6 % cepljenih).
In clinical studies, 57.5% of women aged 16 to 26 years and 31.2% of women aged 24 to 45 years who received Silgard used hormonal contraceptives during the vaccination period. 
V kliničnih študijah je 57,5 % žensk, starih 16 do 26 let, in 31,2 % žensk, starih 24 do 45 let, ki so prejele cepivo Silgard, v obdobju cepljenja uporabljalo hormonske kontraceptive.
Silgard is for prophylactic use only and has no effect on active HPV infections or established clinical disease. 
Cepivo Silgard je samo za profilaktično uporabo in nima učinka na aktivne okužbe s HPV ali na dokazano klinično bolezen.
The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. 
Virusu podobni delci ne vsebujejo virusne DNA in ne morejo okužiti celic, se razmnoževati ali povzročiti bolezni.
GMT- Geometric mean titre in mMU/ml (mMU = milli-Merck units) 
GST- Geometrijski srednji titer v mMe/ml (mMe = mili-Merck enote)
Silgard cannot cause the diseases it protects against. 
Cepivo Silgard ne more povzročiti bolezni, pred katerimi ščiti.
Among 15,706 individuals who received Silgard and 13,617 individuals who received placebo, there were 39 cases of non-specific arthritis/arthropathy reported, 24 in the Silgard group and 15 in the placebo group. 
Med 15.706 osebami, ki so prejele Silgard, in 13.617 osebami, ki so prejele placebo, je bilo 39 poročil o primeru nespecifičnega artritisa/artropatije: 24 v skupini, ki je prejela Silgard, in 15 v skupini, ki je prejela placebo.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z
What Silgard looks like and contents of the pack 1 dose of Silgard suspension for injection contains 0.5 ml. 
Izgled cepiva Silgard in vsebina pakiranja 1 odmerek cepiva Silgard suspenzija za injiciranje vsebuje 0,5 ml suspenzije.
95% CI 
95-odstotni IZ
Persistence of Immune Response of Silgard 
Persistenca imunskega odziva cepiva Silgard
If you forget or are not able to go back to your doctor at the scheduled time, ask your doctor for advice. 
Če ste na dogovorjeni termin pozabili ali ob predvidenem času niste mogli priti, se posvetujte z zdravnikom.
Although fainting episodes are uncommon, patients should be observed for 15 minutes after they receive HPV vaccine. 
Čeprav so omedlevice redke, je treba bolnike po cepljenju s cepivom proti HPV opazovati 15 minut.
When Silgard is given as your first dose, the completion of the vaccination course should be done with Silgard, and not with another HPV vaccine. 
Če kot prvi odmerek prejmete cepivo Silgard, morate cepljenje dokončati s cepivom Silgard in ne s katerim drugim cepivom proti HPV.
An academic study documenting safety and immunogenicity of Silgard has been performed in 126 HIV infected subjects aged from 7 to 12 years (of which 96 received Silgard). 
Akademska študija, v kateri so dokumentirali varnost in imunogenost cepiva Silgard, je bila izvedena pri 126 s HIV okuženih osebah, starih od 7 do 12 let (od katerih jih je 96 prejelo cepivo Silgard).
(95% CI: 67.2, 100) and 100% (95% CI: 55.4, 100), respectively, 
(95-odstotni IZ: 67,2; 100) oz. 100 % (95-odstotni IZ: 55,4; 100);
The final end-of-study results for the combined incidence of CIN 2/3 or AIS in this population after a median follow-up of 3.7 years are shown in Table 4. 
Končni rezultati na koncu študije za kombinirano incidenco CIN 2/3 ali AIS v tej populaciji po medianem času spremljanja do 3,7 leta so prikazani v preglednici 4.
Duration of protection of a 2-dose schedule of Silgard has not been established. 
Trajanje zaščite po 2-odmerni shemi cepljenja s cepivom Silgard ni bilo ugotovljeno.
adsorbed on amorphous aluminium hydroxyphosphate sulphate (0.225 mg Al). 
adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,225 mg Al)
There are no safety, immunogenicity or efficacy data to support change during vaccination with Silgard to other HPV vaccines which do not cover the same HPV types. 
Podatkov o varnosti, imunogenosti ali učinkovitosti, ki bi med obdobjem cepljenja s cepivom Silgard podpirali zamenjavo z drugimi cepivi proti HPV, ki ne vključujejo enakih tipov HPV, ni na voljo.
At 36 month follow-up, the GMT in girls (2 doses, n = 86) remained non-inferior to the GMT in women (3 doses, n = 86) for all 4 HPV types. 
Pri spremljanju v 36. mesecu je GMT pri deklicah (2 odmerka, n = 86) ostal neinferioren od GMT pri ženskah (3 odmerki, n = 86) za vse 4 tipe HPV.
It is recommended that individuals who receive a first dose of Silgard complete the vaccination course 
Priporočljivo je, da osebe, ki so prejele prvi odmerek cepiva Silgard, cepljenje dokončajo s cepivom
In only 1 of 11 specimens HPV 16 was found (at Month 32.5) and was not detected in tissue excised during LEEP (Loop Electro-Excision Procedure). 
HPV 16 je bil odkrit le v enem od 11 vzorcev (po 32,5 mesecih) in ga niso odkrili pri eksciziji tkiva s postopkom LEEP (“Loop Electro-Excision Procedure”).
The median duration of follow-up for the combined protocols (005, 007, 013, and 015) was 3.6 years. 
Mediani čas spremljanja za kombinacijo protokolov (005, 007, 013 in 015) je bil 3,6 leta.
CIN 3 and AIS have been accepted as immediate precursors of invasive cervical 
CIN 3 in AIS sta potrjeno neposredni predstopnji invazivne oblike raka materničnega vratu.
The vaccine should not be mixed in the same syringe with any other vaccines and solutions. 
Cepiva se v isti injekcijski brizgi ne sme mešati z nobenim drugim cepivom ali raztopino.
See sections 4.4 and 5.1 for important information on the data that support this indication. 
Za pomembne podatke, ki podpirajo to indikacijo, glejte poglavji 4.4 in 5.1.
Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of Silgard should not receive further doses of Silgard. 
Osebe, pri katerih se po prejemu odmerka cepiva Silgard pojavijo simptomi preobčutljivosti, nadaljnjih odmerkov cepiva Silgard ne smejo prejeti.
There was no evidence of protection from disease caused by vaccine HPV types for which women were PCR positive at day 1. 
Dokazov o zaščiti pred boleznijo, povzročeno s tipi HPV, ki jih vsebuje cepivo, na katere so bile ženske PCR pozitivne 1. dan, ni bilo.
Overall 12% of the combined study population had an abnormal Pap test suggestive of CIN at Day 1. 
V celoti je 12 % vseh v študijo vključenih oseb imelo 1. dan nenormalni Pap test, ki je kazal na CIN.
Efficacy in women (16 to 45 years) with evidence of a prior infection with a vaccine HPV type (seropositive) that was no longer detectable at vaccination onset (PCR negative) 
Učinkovitost pri ženskah (16 do 45 let) s potrjeno predhodno okužbo s tipom HPV, ki ga vsebuje cepivo (seropozitivne) in ki se ga ob začetku cepljenja ni dalo več določiti (PCR negativne)
Safety was evaluated in either the entire study population (6 studies) or in a predefined subset (one study) of the study population using vaccination report card (VRC)-aided surveillance for 14 days after each injection of Silgard or placebo. 
Varnost so vrednotili bodisi pri celotni populaciji, vključeni v študijo (6 študij), bodisi pri vnaprej določeni podskupini (1 študija) v študijo vključene populacije, na osnovi 14-dnevnega nadzora po vsakem injiciranju cepiva Silgard ali placeba s pomočjo kartončkov za poročanje (vaccination report card (VRC)-aided surveillance).
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE
The need for a booster dose has not been established. 
Potreba po obnovitvenem odmerku ni bila dokazana.
16- to 26-Year-Old Men 
Moški, stari od 16 do 26 let
No minimum antibody level associated with protection has been identified for HPV vaccines. 
Minimalne vrednosti protiteles, povezane z zaščito, za cepiva proti HPV niso bile določene.
This population approximates to the general population of men with respect to prevalence of HPV infection or disease at enrolment. 
Ta populacija je približek splošne populacije moških glede na prevalenco okužbe s HPV ali bolezni zaradi
This is based on the results from a clinical trial in which a combined dTap-IPV vaccine was administered concomitantly with the first dose of Silgard (see section 4.8). 
Opažanje temelji na rezultatih iz kliničnega preskušanja, v katerem so sočasno cepili s kombiniranim cepivom dTap-IPV in prvim odmerkom cepiva Silgard (glejte poglavje 4.8).
In clinical trials, oral or other contraceptives (e.g. the pill) did not reduce the protection obtained by 
Med kliničnimi preskušanji peroralni ali drugi kontraceptivi (npr. kontracepcijske tablete) niso zmanjšali zaščite, dosežene s cepivom Silgard.
The clinical significance of this observation is not known. 
Klinični pomen tega opažanja ni znan.
Silgard will only protect against diseases that are caused by HPV types 6, 11, 16 and 18 and to a limited extent against diseases caused by certain related HPV types (see section 5.1). 
Cepivo Silgard ščiti le pred boleznimi, ki jih povzročajo tipi 6, 11, 16 in 18 HPV, ter v določeni meri pred boleznimi, ki jih povzročajo določeni sorodni tipi HPV (glejte poglavje 5.1).
The vaccine is not used to treat HPV related diseases. 
Cepivo ni namenjeno zdravljenju bolezni, povezanih s HPV.
As expected for women 24 to 45 years of age (Protocol 019), the observed antibody titres were lower than that seen in women 16 to 26 years. 
Kot je bilo pričakovano, so pri ženskah, starih 24 do 45 let (Protokol 019), opazili manjše titre protiteles kot pri ženskah, starih 16 do 26 let.
In the clinical studies, individuals in the Safety Population reported any new medical conditions during the follow-up. 
V kliničnih študijah so posamezniki iz populacije, v kateri so podrobneje spremljali varnost cepiva, v času spremljanja poročali o kateri koli spremembi zdravstvenega stanja.
Therefore, appropriate precautions against sexually transmitted diseases should continue to be used. 
Zato je treba previdnostne ukrepe za preprečevanje prenosa spolno prenosljivih bolezni izvajati še naprej.
The clinical relevance of the lower response is unknown. 
Klinični pomen manjšega odgovora ni znan.
As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine. 
Tako kot pri vseh cepivih, ki se jih injicira, je treba vedno zagotoviti ustrezno obliko zdravljenja, ki bo v redkih primerih anafilaktične reakcije po cepljenju nemudoma na voljo.
Immune Responses to Silgard at 1 month post dose 3 
Imunski odziv na cepivo Silgard 1 mesec po 3. odmerku
The CD4% or plasma HIV RNA was not affected by vaccination. 
Cepljenje ni vplivalo na % CD4 ali vrednost HIV RNA v plazmi.
The primary analysis was done in type-specific populations that required women to be negative for the type being analyzed, but who could be positive for other HPV types (96% of the overall population). 
Ženske so morale biti negativne za preiskovani tip, lahko pa so bile pozitivne za druge tipe HPV (96 % celotne populacije).
HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response. 
S HPV se okuži le človek, vendar pa študije z analognimi papilomavirusi na živalih kažejo, da je učinkovitost L1 VLP cepiv posledica spodbujanja humoralnega
Very rarely (less than 1 in 10,000 patients), difficulty breathing (bronchospasm) has been reported. 
Zelo redki (pri manj kot 1 od 10.000 cepljenih oseb): Poročali so o težavah z dihanjem (bronhospazem).
What other important information should you or your child know about Silgard 
Drugi pomembni podatki o cepivu Silgard, ki jih morate vi ali vaš otrok poznati
Silgard must not be injected intravascularly. 
Cepiva Silgard se ne sme injicirati intravaskularno.
In the ITT population the corresponding reduction was 23.9% (95% CI: 15.2, 31.7). 
V ITT populaciji je ustrezen delež zmanjšanja znašal 23,9 % (95-odstotni IZ: 15,2; 31,7).
Silgard does not have any effect in individuals who already have a persistent infection or disease associated with any of the HPV types in the vaccine. 
Cepivo Silgard ne učinkuje pri osebah, ki že imajo persistentno okužbo ali bolezen, povezano s katerim koli tipom HPV, ki ga vsebuje cepivo.
The efficacy for all other endpoints is based on protocols 007, 013, and 015. 
Učinkovitost proti vsem drugim opazovanim dogodkom temelji na protokolih 007, 013 in 015.
The seroprotection rates (proportion of individuals reaching seroprotective level anti-HBs >10 mIU/ml) were unaffected (96.5% for concomitant vaccination and 97.5% for hepatitis B vaccine only). 
Odstotek serozaščite (delež oseb, pri katerih je bila dosežena raven serozaščite anti-HBs > 10 mi.e./ml) je ostal nespremenjen (96,5 % pri sočasnem cepljenju in 97,5 % pri cepljenju samo s cepivom proti hepatitisu B).
• Shake well before use to make a suspension. 
• Pred uporabo dobro pretresite, da nastane suspenzija.
The vaccine should be administered by intramuscular injection. 
Cepivo je treba aplicirati intramuskularno.
In the same study, in girls aged 9-13 years, the immune response after a 2-dose schedule was numerically lower than after a 3-dose schedule (n = 248 at Month 7; n = 82 at Month 36). 
V isti študiji pri deklicah, starih 9 do 13 let, je bil imunski odziv po 2-odmerni shemi cepljenja številčno manjši kot po 3-odmerni shemi (n = 248 v 7. mesecu; n = 82 v 36. mesecu).
A clinical trial showed that among girls who received 2 doses of HPV vaccine 6 months apart, antibody responses to the 4 HPV types, one month after the last dose were non-inferior to those among young women who received 3 doses of the vaccine within 6 months. 
Klinično preskušanje je pokazalo, da je bil med deklicami, ki so prejele 2 odmerka cepiva proti HPV v razmiku 6 mesecev, odziv protiteles na 4 tipe HPV en mesec po zadnjem odmerku neinferioren od odziva pri mladih ženskah, ki so prejele 3 odmerke cepiva v roku 6 mesecev.
HPV 6 and 11 are responsible for approximately 90% of genital warts and 10% of low grade cervical intraepithelial neoplasia (CIN 1). 
HPV 6 in 11 sta odgovorna za približno 90 % primerov bradavic na spolovilih in 10 % cervikalne intraepitelijske neoplazije nizke stopnje (CIN 1).
• Third injection: 6 months after first injection The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. 
• Tretja injekcija: 6 mesecev po prvi injekciji Drugi odmerek je treba dati vsaj en mesec po prvem odmerku, tretji odmerek pa vsaj 3 mesece po drugem odmerku.
The studies were not powered to assess efficacy against disease caused by individual HPV types. 
Študije niso omogočale vrednotenja učinkovitosti proti boleznim zaradi posameznih tipov HPV.
However, a mild fever or upper respiratory infection (for example cold) itself is not a reason to delay vaccination. 
Rahlo zvišana telesna temperatura ali okužba zgornjih dihal (na primer prehlad) nista razlog za odložitev cepljenja.
Administration of Silgard at the same time (but, for injected vaccines, at a different injection site) as hepatitis B (recombinant) vaccine did not interfere with the immune response to the HPV types. 
Dajanje cepiva Silgard sočasno (vendar na različna mesta, če gre za cepiva, ki se injicirajo) in rekombinantnega cepiva proti hepatitisu B ni vplivalo na imunski odziv na tipe HPV.
There have been reports of administration of higher than recommended doses of Silgard. 
Poročali so o dajanju odmerkov cepiva Silgard, ki so bili večji od priporočenih.
Hypersensitivity to the active substances or to any of the excipients. 
Preobčutljivost za zdravilne učinkovine ali katero koli pomožno snov.
For any information about this medicinal product, please contact the local representative of the 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika
The vaccine also produces type-specific antibodies in 9- to 15-year-old children and adolescents. 
Nastajanje tipsko specifičnih protiteles povzroči tudi pri 9 do 15 let starih otrocih in
Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives and rash have been reported. 
Alergijske reakcije, ki lahko vključujejo težko dihanje, sopenje (bronhospazem), koprivnico in izpuščaj; nekatere od teh reakcij so bile hude.
At end of study, individuals enrolled in the two Phase-III studies (Protocol013 and Protocol-015), were followed for up to 4 years (median 3.7 years). 
Na koncu študije je bil čas spremljanja oseb, vključenih v dve študiji III. faze (Protokol 013 in Protokol 015), do 4 leta (mediana 3,7 let).
Rarely (less than 1 in 1000 patients): hives (urticaria). 
Redki (pri manj kot 1 od 1.000 cepljenih oseb): koprivnica (urtikarija).
Few individuals (0.2%) discontinued due to adverse reactions. 
Zaradi neželenih učinkov je bilo iz preskušanj izključenih le nekaj oseb (0,2 %).
Individuals with impaired immune responsiveness, due to either the use of potent immunosuppressive therapy, a genetic defect, or other causes, may not respond to the vaccine. 
Pri osebah z imunsko pomanjkljivostjo zaradi agresivnega imunosupresivnega zdravljenja, genetske okvare ali drugih vzrokov odziv na cepljenje morda ne bo dosežen.
For composite endpoints, statistically significant efficacy against disease was demonstrated against HPV types phylogenetically related to HPV 16 (primarily HPV 31) whereas no statistically significant efficacy was observed for HPV types phylogenetically related to HPV 18 (including HPV 45). 
Za sestavljene opazovane dogodke so statistično značilno učinkovitost proti bolezni ugotovili za tipe HPV, ki so filogenetsko sorodni HPV 16 (primarno HPV 31), medtem ko za tipe HPV, ki so filogenetsko sorodni HPV 18 (vključno s HPV 45) statistično značilne učinkovitosti niso opazili.
HPV types 6 and 11 are responsible for approximately 90% of 
HPV tipa 6 in 11 sta odgovorna za približno 90 % primerov bradavic na spolovilih.
Table 5: Efficacy of Silgard against external genital lesions in the PPE* population of 16-26 year old 
Preglednica 5: Učinkovitost cepiva Silgard proti lezijam na zunanjih spolovilih v populaciji PPE* moških, starih od 16 do 26 let
The use of Silgard in adult women should take into consideration the variability of HPV type prevalence in different geographical areas. 
Pri uporabi cepiva Silgard pri odraslih ženskah je treba upoštevati variabilnost v razširjenosti tipa HPV
In addition, a subset of vaccinated women who received a challenge dose of Silgard 5 years after the onset of vaccination, exhibited a rapid and strong anamnestic response that exceeded the anti-HPV GMTs observed 1 month Postdose 3. 
Razen tega so pri cepljenih ženskah, ki so 5 let po začetku cepljenja prejele obnovitveni odmerek cepiva Silgard opazili hiter in močan anamnestični odziv, ki je presegel srednje geometrijske titre anti HPV, opažene 1 mesec po cepljenju s
However, the presence of a minor infection, such as a mild upper respiratory tract infection or low-grade fever, is not a contraindication for immunisation. 
Vendar pa blažja okužba, kot sta blaga okužba zgornjih dihal ali rahlo zvišana telesna temperatura, ni kontraindikacija za cepljenje.
Immunogenicity was related to age and Month 7 anti-HPV levels were significantly higher in younger individuals. 
Imunogenost je bila povezana s starostjo, ravni anti-HPV 7. mesec pa so bile pri mlajših osebah
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi cepiva, se posvetujte z zdravnikom ali farmacevtom.
At Month 7, in the Per Protocol population, the immune response in girls aged 9-13 years (n = 241) who received 2 doses of Silgard (at 0, 6 months) was non-inferior and numerically higher to the immune response in women aged 16-26 years (n = 246) who received 3 doses of Silgard (at 0, 2, 
V 7. mesecu je bil imunski odziv v populaciji per protocol pri deklicah, starih od 9 do 13 let (n = 241), ki so prejele 2 odmerka cepiva Silgard (v 0. in 6. mesecu), neinferioren in je bil številčno večji kot imunski odziv pri ženskah, starih od 16 do 26 let (n = 246), ki so prejele 3 odmerke cepiva Silgard (v 0., 2. in 6. mesecu).
• you or your child developed an allergic reaction after receiving a dose of Silgard. 
• če se je pri vas ali vašem otroku po cepljenju z odmerkom cepiva Silgard pojavila alergijska reakcija;
Evidence of an anamnestic response was seen in vaccinated women who were seropositive to relevant HPV type(s) prior to vaccination. 
Dokaz anamnestičnega odziva so zasledili pri cepljenih ženskah, ki so bile pred cepljenjem seropozitivne na relevantni tip (relevantne tipe) HPV.
After thorough agitation, it 
Ko ga dobro pretresemo, je
Type-specific immunoassays, competitive Luminex-based immunoassay (cLIA), with type-specific standards were used to assess immunogenicity to each vaccine type. 
Imunogenost vsakega od vakcinalnih tipov je bila ovrednotena s tipsko specifičnim imunskim testom (competitive Luminex-based immunoassay - cLIA), pri čemer so bili uporabljeni tipsko specifični standardi.
Silgard will not protect against every type of Human Papillomavirus. 
Cepivo Silgard ne ščiti pred vsakim tipom humanih papilomavirusov.
The median duration of follow-up for these studies was 4.0, 3.0, 3.0, and 3.0 years for Protocol 005, Protocol 007, Protocol 013, and Protocol 015, respectively. 
Mediani čas spremljanja v teh študijah je bil 4,0 leta za Protokol 005, ter 3,0 leta za Protokol 007, Protokol 013 in Protokol 015.